The earnings call highlights strong revenue growth, clinical trial progress, and strategic expansions in managed care and certification, offset by increased operating expenses and continued GAAP loss. Overall, the positive aspects significantly outweigh the lowlights.

Company Guidance -

Q3 2025

During the Fulgent Genetics Q2 2025 conference call, the company reported a robust performance with core revenue reaching $81.7 million, reflecting a 16% year-over-year and 11% sequential increase. Precision Diagnostics rose by 7%, Biopharma Services by 54%, and Anatomic Pathology by 11%. The company's gross margin on a non-GAAP basis was 44.2%, while GAAP gross margin was 42.1%. Operating expenses increased, with non-GAAP operating expenses at $43.9 million and total GAAP operating expenses at $54.1 million. The company reported a GAAP loss of $19 million, influenced by a $9.9 million impairment charge. Non-GAAP income was $2.1 million, equating to $0.07 per share. Fulgent revised its 2025 revenue guidance upwards to $320 million and improved its non-GAAP EPS guidance to a loss of $0.35 per share. It ended the quarter with $777.5 million in cash and investments, anticipating a year-end cash position of approximately $770 million.

Strong Revenue Growth

Core revenue reached $81.7 million, up 16% year-over-year and 11% sequentially, driven by growth in Precision Diagnostics (7%), Biopharma Services (54%), and Anatomic Pathology (11%).

Positive Updates in Clinical Trials

FID-007 is progressing well in Phase II trials, with 32 patients enrolled. Patient enrollment is expected to complete by the end of 2025. FID-022's Phase I trial has also begun with the first patient cohort enrolled.

New Product Launches and CE Mark Certification

Launched a new whole genome sequencing service with advanced features. Received CE Mark for Fulgent exome and Fulgent Pipeline Manager, facilitating expansion into European markets.

Managed Care Expansion

Since January, over 20 new agreements were executed, adding over 35 million new covered lives to in-network contracts.

Improved Financial Guidance

Increased annual revenue guidance for 2025 from $310 million to $320 million, representing a 14% year-over-year growth. Expected improvements in non-GAAP EPS and operating margins.

Fulgent Genetics (FLGT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FLGT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.20 / -	0.31	―	―	―
Aug 01, 2025	2025 (Q2)	-0.18 / 0.07	0.15	-53.33% (-0.08)
May 02, 2025	2025 (Q1)	-0.18 / 0.04	-0.01	500.00% (+0.05)	―
Feb 28, 2025	2024 (Q4)	-0.12 / 0.04	0.28	-85.71% (-0.24)	―
Nov 08, 2024	2024 (Q3)	-0.15 / 0.31	-0.39	179.49% (+0.70)
Aug 02, 2024	2024 (Q2)	-0.30 / 0.15	-0.08	287.50% (+0.23)
May 03, 2024	2024 (Q1)	-0.32 / -0.01	-0.22	95.45% (+0.21)
Feb 28, 2024	2023 (Q4)	-0.29 / 0.28	-0.48	158.33% (+0.76)
Nov 03, 2023	2023 (Q3)	-0.32 / -0.39	0.32	-221.88% (-0.71)
Aug 04, 2023	2023 (Q2)	-0.33 / -0.08	0.78	-110.26% (-0.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FLGT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 02, 2025	$17.25	$20.54	+19.07%
Feb 28, 2025	$15.69	$15.45	-1.53%
Nov 08, 2024	$22.02	$19.43	-11.76%
Aug 02, 2024	$23.57	$25.06	+6.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fulgent Genetics Inc (FLGT) report earnings?

Fulgent Genetics Inc (FLGT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Fulgent Genetics Inc (FLGT) earnings time?

Fulgent Genetics Inc (FLGT) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FLGT EPS forecast?

FLGT EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing